Sulprostone in the control of postpartum haemorrhage.
A PGE2 analogue, Sulprostone was administered to control the postpartum haemorrhage, immediately after the baby was born, to 74 healthy patients, who had normal pregnancy and delivery. Divided into three groups they received 50 or 100 micrograms intravenously, or 200 micrograms intramuscularly. The results were compared with those of a group of 54 patients, which received 0.2 mg methylergometrine i.m. and 5 IU oxytocin i.v. respectively. The blood loss was measured during the third stage of labour and during two hours thereafter. The pilot dose of 50 micrograms was not effective enough. The blood loss in the group of 100 micrograms i.v. was 386 +/- 175 ml, in the group of 200 micrograms i.m. 325 +/- 197 ml, and in the methylergometrine-oxytocin group 302 +/- 202 ml. Sulprostone 200 micrograms i.m. seems to be effective treatment to control the postpartum haemorrhage. Only four patients had mild side-effects after Sulprostone administration.
D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D007749:Labor Stage, Third / Q000187:drug effects; D008755:Methylergonovine / Q000627:therapeutic use; D010121:Oxytocin / Q000627:therapeutic use; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*
D011459:Prostaglandins E, Synthetic; D010121:Oxytocin; C016767:sulprostone; D015232:Dinoprostone; D008755:Methylergonovine